In one of these studies, cetuximab was reported to have superior activity in patients carrying FcRIIa-131H or FcRIIIa-158V alleles, a result that has previously been reported for other therapeutic antibodies.19Similar correlations for FcRIIa, but surprisingly different results with respect to FcRIIIa, were reported in a second study.20Since FcRIIa is predominantly expressed by myeloid effector cells, […]